Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Market Cap$1.28B
Close$
$26.51
62.7% downside
Current Fair Value
62.7% downsideOvervalued by 62.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.28 Billion |
|---|---|
| Enterprise Value | $1.11 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $2.94 |
| Beta | 0.95 |
| Outstanding Shares | 17,705,287 |
| Avg 30 Day Volume | 150,767 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 24.62 |
|---|---|
| PEG | -12.07 |
| Price to Sales | 10.14 |
| Price to Book Ratio | 1.82 |
| Enterprise Value to Revenue | 8.48 |
| Enterprise Value to EBIT | 113.4 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins